GlaxoSmithKline (GSK) and Theravance have obtained approval from the Japanese Ministry of Health, Labour and Welfare for Anoro Ellipta to treat chronic obstructive pulmonary disease (COPD).
The Japanese approval for Anoro Ellipta is for the relief of various symptoms due to airway obstruction with COPDs, in the case where concurrent use of long-acting inhaled muscarinic antagonist and long-acting inhaled beta2 agonist is required
GSK and Theravance announce Japanese approval for Anoro Ellipta
GlaxoSmithKline (GSK) and Theravance have obtained approval from the Japanese Ministry of Health, Labour and Welfare for Anoro Ellipta to treat chronic obstructive pulmonary disease (COPD).
